diarylguanidines are structurally unrelated to known blockers of nmda channels and , therefore , represent a new compound series for the development of neuroprotective agents with therapeutic value in patients suffering from stroke , from brain or spinal cord trauma , from hypoglycemia , and possibly from brain ischemia due to heart attack .
C0038454
stroke
C0006104
brain